124 related articles for article (PubMed ID: 7634247)
21. Prognostic value of the immunomonitoring of patients with renal cell carcinoma under therapy with IL-2/IFN-alpha-2 in combination with 5-FU.
Göhring B; Riemann D; Rebmann U; Heynemann H; Schabel J; Langner J
Urol Res; 1996; 24(5):297-303. PubMed ID: 8931295
[TBL] [Abstract][Full Text] [Related]
22. Interferon is able to reduce tumor cell susceptibility to human lymphokine-activated killer (LAK) cells.
Grönberg A; Ferm M; Tsai L; Kiessling R
Cell Immunol; 1989 Jan; 118(1):10-21. PubMed ID: 2463094
[TBL] [Abstract][Full Text] [Related]
23. Human renal carcinoma line transfected with interleukin-2 and/or interferon alpha gene(s): implications for live cancer vaccines.
Belldegrun A; Tso CL; Sakata T; Duckett T; Brunda MJ; Barsky SH; Chai J; Kaboo R; Lavey RS; McBride WH
J Natl Cancer Inst; 1993 Feb; 85(3):207-16. PubMed ID: 8423625
[TBL] [Abstract][Full Text] [Related]
24. Mutated Von Hippel-Lindau-renal cell carcinoma (RCC) promotes patients specific natural killer (NK) cytotoxicity.
Trotta AM; Santagata S; Zanotta S; D'Alterio C; Napolitano M; Rea G; Camerlingo R; Esposito F; Lamantia E; Anniciello A; Botti G; Longo N; Botti G; Pignata S; Perdonà S; Scala S
J Exp Clin Cancer Res; 2018 Dec; 37(1):297. PubMed ID: 30514329
[TBL] [Abstract][Full Text] [Related]
25. The effectors of killer activity induced by interferon-alpha and gamma in peripheral blood mononuclear cells.
Sakaguchi M; Kubota S; Nishikido M; Taniguchi K; Inuzuka S; Saito Y; Kanetake H; Koga S
Int J Mol Med; 2002 Sep; 10(3):317-20. PubMed ID: 12165807
[TBL] [Abstract][Full Text] [Related]
26. Changes in immunological parameters during interleukin 2 and interferon 2 alpha treatment of recurrent renal cell carcinoma and malignant melanoma.
Maxwell W; McDevitt J; Reid I; Sharpe I; Feighery C; Tanner WA; Emmons R; Monson JR
Eur J Surg Oncol; 1993 Jun; 19(3):265-72. PubMed ID: 8314385
[TBL] [Abstract][Full Text] [Related]
27. Resistance of chronic lymphocytic leukaemia cells to interferon-alpha generated lymphokine activated killer cells.
Jewell AP; Worman CP; Giles FJ; Goldstone AH; Lydyard PM
Leuk Lymphoma; 1992 Aug; 7(5-6):473-80. PubMed ID: 1362916
[TBL] [Abstract][Full Text] [Related]
28. Enhanced susceptibility of cis-diamminedichloroplatinum-treated K562 cells to lysis by peripheral blood lymphocytes and lymphokine activated killer cells.
Mizutani Y; Bonavida B; Nio Y; Yoshida O
Cancer; 1993 Feb; 71(4):1313-21. PubMed ID: 7679609
[TBL] [Abstract][Full Text] [Related]
29. Human tumor cell line resistance to chemotherapeutic agents does not predict resistance to natural killer or lymphokine-activated killer cell-mediated cytolysis.
Harker WG; Tom C; McGregor JR; Slade L; Samlowski WE
Cancer Res; 1990 Sep; 50(18):5931-6. PubMed ID: 1975512
[TBL] [Abstract][Full Text] [Related]
30. Functional and phenotypic modifications induced by IL-4, as single agent or in combination with IL-2, on PBMC preactivated in vivo by alpha-interferon + interleukin-2 therapy.
Favrot M; Capdeville R; Combaret V; Zhou DC; Clapisson G; Banchereau J; Franks CR; Chouaib S; Blay JY; Philip T
Eur Cytokine Netw; 1990; 1(3):141-7. PubMed ID: 2129798
[TBL] [Abstract][Full Text] [Related]
31. Higher susceptibility of erythropoietin-producing renal cell carcinomas to lysis by lymphokine-activated killer cells.
Miyajima J; Imai Y; Nakao M; Noda S; Itoh K
J Immunother Emphasis Tumor Immunol; 1996 Nov; 19(6):399-404. PubMed ID: 9041458
[TBL] [Abstract][Full Text] [Related]
32. [Expression of major histocompatibility complex antigens and adhesion molecules on renal cell carcinoma cells, and effect of interferon-alpha and/or cimetidine on the expression].
Wu XX; Mizutani Y; Kakehi Y; Nakamura E; Mitsumori K; Takahashi T; Terachi T; Okada Y; Yoshida O
Hinyokika Kiyo; 1998 Sep; 44(9):621-6. PubMed ID: 9805665
[TBL] [Abstract][Full Text] [Related]
33. Biomodulation of 5-fluorouracil by interferon-alpha in human renal carcinoma cells: relationship to the expression of thymidine phosphorylase.
Morita T; Tokue A
Cancer Chemother Pharmacol; 1999; 44(2):91-6. PubMed ID: 10412941
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of murine renal carcinoma pulmonary metastases by systemic administration of interferon gamma: mechanism of action and potential for combination with interleukin 4.
Hillman GG; Younes E; Visscher D; Hamzavi F; Kim S; Lam JS; Montecillo EJ; Ali E; Pontes JE; Puri RK; Haas GP
Clin Cancer Res; 1997 Oct; 3(10):1799-806. PubMed ID: 9815566
[TBL] [Abstract][Full Text] [Related]
35. Renal cell carcinoma-infiltrating natural killer cells express differential repertoires of activating and inhibitory receptors and are inhibited by specific HLA class I allotypes.
Schleypen JS; Von Geldern M; Weiss EH; Kotzias N; Rohrmann K; Schendel DJ; Falk CS; Pohla H
Int J Cancer; 2003 Oct; 106(6):905-12. PubMed ID: 12918068
[TBL] [Abstract][Full Text] [Related]
36. Natural cytotoxicity of human blood lymphocytes and monocytes and their cytotoxic factors: effect of interferon on target cell susceptibility.
Uchida A; Vánky F; Klein E
J Natl Cancer Inst; 1985 Nov; 75(5):849-57. PubMed ID: 2414505
[TBL] [Abstract][Full Text] [Related]
37. Combination of lymphokine-activated killer cells and interleukin-2 in treating metastatic renal cell carcinoma.
Fujioka T; Nomura K; Hasegawa M; Ishikura K; Kubo T
Br J Urol; 1994 Jan; 73(1):23-31. PubMed ID: 8298895
[TBL] [Abstract][Full Text] [Related]
38. Human renal-cell carcinoma cells are able to activate natural killer cells.
Hayakawa K; Morita T; Augustus LB; von Eschenbach AC; Itoh K
Int J Cancer; 1992 May; 51(2):290-5. PubMed ID: 1533204
[TBL] [Abstract][Full Text] [Related]
39. [A new interferon-alpha assay system including indirect antitumor effect. Basic and clinical study of renal cell carcinoma].
Yoshihiro S
Nihon Hinyokika Gakkai Zasshi; 1992 Mar; 83(3):338-47. PubMed ID: 1564836
[TBL] [Abstract][Full Text] [Related]
40. The relationship between multi-drug resistance and resistance to natural-killer-cell and lymphokine-activated killer-cell lysis in human leukemic cell lines.
Treichel RS; Olken S
Int J Cancer; 1992 Jan; 50(2):305-10. PubMed ID: 1370437
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
